Article ; Online: Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial.
2021 Volume 21, Issue 1, Page(s) 297
Abstract: Background: Levamisole has shown clinical benefits in the management of COVID-19 via its immunomodulatory effect. However, the exact role of Levamisole effect in clinical status of COVID-19 patients is unknown. We aimed to evaluate the efficacy of ... ...
| Abstract | Background: Levamisole has shown clinical benefits in the management of COVID-19 via its immunomodulatory effect. However, the exact role of Levamisole effect in clinical status of COVID-19 patients is unknown. We aimed to evaluate the efficacy of Levamisole on clinical status of patients with COVID-19 during their course of the disease. Methods: This prospective, double-blind, randomized controlled clinical trial was performed in adult patients with mild to moderate COVID-19 (room-air oxygen saturation > 94%) from late April 2020 to mid-August 2020. Patients were randomly assigned to receive a 3-day course of Levamisole or placebo in combination with routine standard of care. Results: With 25 patients in each arm, 50 patients with COVID-19 were enrolled in the study. Most of the study participants were men (60%). On days 3 and 14, patients in Levamisole group had significantly better cough status distribution when compared to the placebo group (P-value = 0.034 and 0.005, respectively). Moreover, there was significant differences between the two groups in dyspnea at follow-up intervals of 7 (P-value = 0.015) and 14 (P-value = 0.010) days after receiving the interventions. However, no significant difference in fever status was observed on days 1, 3, 7, and 14 in both groups (P-value > 0.05). Conclusion: The results of the current study suggest that Levamisole may improve most of clinical status of patients with COVID-19. The patients receiving Levamisole had significantly better chance of clinical status including cough and dyspnea on day 14 when compared to the placebo. However, the effect-size of this finding has uncertain clinical importance. Trial registration: The trial was registered as IRCT20190810044500N7 (19/09/2020). |
|---|---|
| MeSH term(s) | Adult ; Double-Blind Method ; Female ; Humans ; Levamisole/therapeutic use ; Male ; Middle Aged ; Prospective Studies ; Time Factors ; Treatment Outcome ; Young Adult ; COVID-19 Drug Treatment |
| Chemical Substances | Levamisole (2880D3468G) |
| Language | English |
| Publishing date | 2021-03-24 |
| Publishing country | England |
| Document type | Journal Article ; Randomized Controlled Trial |
| ZDB-ID | 2041550-3 |
| ISSN | 1471-2334 ; 1471-2334 |
| ISSN (online) | 1471-2334 |
| ISSN | 1471-2334 |
| DOI | 10.1186/s12879-021-05983-2 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.